Clinical trials: Other
Advanced Cancer, Colorectal Cancer
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.
- Conditions
- Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
- Trial name
- NCT02745769
- Testing
- Ramucirumab, Merestinib, Abemaciclib
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Therapeutic Drug Monitoring for Individualized Clozapine Therapy
The purpose of this study is to evaluate the factors affecting the occurrence of adverse drug reactions (glucose and lipid metabolism abnormality, changes in liver function index and sleeping tendency) and clinical effects in…
- Trial name
- NCT03523741
- Testing
- Clozapine
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia
Treatment of Zollinger-Ellison Syndrome With Prevacid
The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
- Trial name
- NCT00204373
- Testing
- Lansoprazole (Prevacid)
- Volunteers
- 72 people
- Sponsor
- Charles Mel Wilcox, MD
Healthy
A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults
The purpose of this study is to learn how the medicine called itraconazole and food changes how the body processes another study medicine called PF-07258669 in older adults or healthy adults.
- Trial name
- NCT06706869
- Testing
- PF-07258669, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chagas' Disease (Chronic) With Other Organ Involvement
Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation
Chagas disease is one of the most neglected vector-borne infectious disease worldwide. The first decades following the discovery of the pathology drove an international research enthusiasm, mainly concentrated on understanding…
- Trial name
- NCT03189056
- Testing
- Chagas serology, Creatinina, Urodynamic exploration
- Where
- Bolivia
- Volunteers
- 152 people
- Sponsor
- Institut de Recherche pour le Developpement
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations…
- Trial name
- DOLAF (NCT04053322)
- Testing
- Durvalumab, Olaparib, Fulvestrant
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- UNICANCER
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Schizophrenia, Bipolar Disorder
Approaches For ThE pRioritization of Patients in priMAry Care Post-COVID To Reduce Health Inequities (AFTERMATH)
The COVID-19 pandemic significantly impacted primary care across Canada. Inequities in prevention activities and chronic disease management likely increased but the extent is unknown.
- Trial name
- AFTERMATH (NCT05823805)
- Testing
- Community Health Worker
- Volunteers
- 520 people
- Sponsor
- Unity Health Toronto
Schizophrenia
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to…
- Trial name
- CANGLIA (NCT02932605)
- Testing
- Cannabidiol
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- UMC Utrecht
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00055653
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 25 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Computer Simulation, Energy Expenditure
Modelling of Energy Expenditure From Heart Rate, Accelerometry and Other Physiological Parameters
At this time, 24h energy expenditure is rarely assessed under free-living conditions for specific individuals because of the lack of cheap and accurate software/materials to record the energy expenditure.
- Conditions
- Computer Simulation, Energy Expenditure, Energy Metabolism
- Trial name
- Modelheart (NCT01209572)
- Testing
- calorimetric chamber, Free living conditions
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Stress Disorders, Post-Traumatic, Alcohol Abuse
Combined Treatment for Alcohol-Dependent Individuals With PTSD
This treatment intervention trial is designed for men and women with either alcohol misuse (e.g. hazardous or binge drinking) or alcohol use disorders (alcohol abuse or dependence) and comorbid PTSD.
- Conditions
- Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
- Trial name
- NCT00262223
- Testing
- Seeking Safety, Sertraline
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Blooddraw
Family-based Genetic Long-term Study of Brain Function in Schizophrenia
The goal of this research is to find out possible susceptible gene(s) in schizophrenic patients with family history and 5-year period functional changes of brain among the members of family, in order to further analysis factors…
- Conditions
- Schizophrenia, Blooddraw, MRI
- Trial name
- FamilySchizo (NCT01045824)
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- Taichung Veterans General Hospital
Health Services Accessibility, Blood Coagulation Factor Deficiencies
Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies
The current treatment of people with haemophilia and other bleeding deficiencies is largely based on clotting factor replacement therapy. The injections can be repeated several times a week according to a personalized schedule.
- Trial name
- PHAREO (NCT04775888)
- Where
- 34 sites in France
- Volunteers
- 500 people
- Sponsor
- RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Schizophrenia
Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia
Repetitive transcranial magnetic stimulation (rTMS) is a new noninvasive therapy that uses magnetic energy applied to the scalp to modulate activity in the underlying regions of the brain.
- Trial name
- NCT01595503
- Testing
- rTMS with fMRI-based targeting, rTMS with landmark-based targeting
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Schizophrenia
24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
The purpose of this open-label study was to evaluate the safety and tolerability of flexible doses of Extended Release OROS® Paliperidone in the treatment of geriatric subjects with schizophrenia after completion of the initial…
- Trial name
- NCT00752427
- Testing
- Paliperidone ER OROS®
- Volunteers
- 86 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Multiple Sclerosis, Relapsing-Remitting
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.
- Trial name
- ROBUST (NCT01158183)
- Testing
- BAY86-5046_Interferon-beta-1b
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Bayer
Schizophrenia
Schizophrenia and Genetic Counseling
This research is designed to investigate the perceptions and opinions of individuals who either have schizophrenia or who have a family member with schizophrenia, in relation to genetic counseling.
- Trial name
- NCT00111202
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sarah Lawrence College
Head and Neck, Squamous Cell Cancer
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well.
- Trial name
- NCT00661427
- Testing
- cetuximab
- Where
- 17 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prodromal Schizophrenia, Psychosis
Feasibility Trial of a Lifestyle Intervention for CHR-P
The present study will assess the feasibility and social validity of an adjunctive health promotion group for youth and clinical high risk for psychosis (CHR-P).
- Conditions
- Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
- Trial name
- NCT05532683
- Testing
- Health Behaviors Group
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, Los Angeles